Efficacy and safety analysis of letermovir for the prevention of CMV infection after haploidentical hematopoietic stem cell transplantation in children with acute leukemia (ASH 2025) - Nov 4, 2025 - Abstract #abs25-13918; 2440; Pres time: Dec 6, 2025; 05:30 PM - 07:30 PM; Location: OCCC - West Halls B3-B4; "For children with acute leukemia who undergo haploidentical hematopoietic stem celltransplantation (Haplo-HSCT), the use of letermovir for the prevention of cytomegalovirus (CMV) infectionafter transplantation is effective. It does not increase the incidence of Epstein-Barr virus (EBV) infection orthe incidence of grade II-IV acute graft-versus-host disease (aGVHD), and it improves the 3-year survivalrate and reduces the 3-year recurrence rate."
Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation • CD34
|
|
Huili Zhu1; Zhijie Wei1; Peihua Lu1
|